Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Document › Details

Hadean Ventures. (12/18/17). "Press Release: Hadean Ventures Launches New Fund to Leverage Untapped Potential of European Life Science Start-ups". Oslo & Stockholm.

Region Region Scandinavia
Organisations Organisation Hadean Capital I fund
  Group Hadean Ventures (NO)
  Organisation 2 Argentum
Products Product venture capital
Index term Index term Hadean Ventures–SEVERAL: investment, 201712 closing €100m of Hadean Capital I fund incl investors Argentum + Saminvest et al.
Persons Person Akay, Ingrid Teigland (Hadean Ventures 201604 Managing Director)
  Person 2 Stockinger, Walter (Hadean Ventures 201712 Managing Partner)

Hadean Ventures announced today the closing of Hadean Capital I, a new fund with a target size of €100 million that will invest in life science companies. A particular attention will be given to regions of Europe harbouring world class scientific communities, yet are under-served from a venture capital perspective, especially the Nordic region. The fund is supported by a consortium of blue chip fund investors, including Argentum, Saminvest, Gjensidigestiftelsen, OPF and Varner.

Ingrid Teigland Akay, Managing Partner of Hadean Ventures, says: “Several European countries have built world class scientific communities on the basis of longstanding tradition for scientific excellence and significant investments in research. In addition, the growing ecosystem and surge in entrepreneurship have created a very fertile ground for life science start-ups. In particular, the Nordic region has outstanding scientists, a stable, business friendly environment and a vibrant start-up community, yet very few life science specialist venture funds are on the ground. We see an exceptionally strong deal flow of high potential opportunities here.”

Walter Stockinger, Managing Partner of Hadean Ventures, points out that “the availability of venture capital for life science start-ups has not kept pace with the recent entrepreneurial boom. Other industries have seen several new VC funds emerge, supporting and benefiting from the surge in young and innovative companies, whereas the complexity of the healthcare sector presents a particularly high hurdle. Our team combines the necessary life science know-how with many years of VC experience, which we believe enables us to identify and accelerate high potential life science start-ups and benefit from the particularly fertile environment.”

Joachim Høegh-Krohn, CEO of Argentum, says: “We invest in Hadean Ventures because we believe in the healthcare growth potential and Hadean Ventures' ability to find and further develop companies that solve tomorrow's health challenges”.

“I am delighted that Saminvest invests in the emerging team of Hadean Ventures. We firmly believe that the new fund is well positioned to take advantage of the investment opportunities in the fast growing and innovative life science sector in Scandinavia”, says Peder Hasslev, Chief Executive Officer at Saminvest.

Hadean Ventures has offices in Oslo and Stockholm and collaborates with start-up hubs across the region.

Record changed: 2017-12-22


Picture [iito] Plain Stupid Simple 650x80px

More documents for Hadean Ventures (NO)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC E Hand 650x300px

» top